



7/13/06 | Press Release

### **DAVA Pharmaceuticals, Inc. Announces Acquisition of STADA, Inc.**

Fort Lee, New Jersey, July 13, 2006 – DAVA Pharmaceuticals, Inc. (“DAVA”) announced today that it has entered into an agreement with STADA Arzneimittel AG for the purchase of its wholly-owned subsidiary, STADA, Inc. STADA, Inc. owns and operates STADA AG’s U.S. generic pharmaceutical business.

“The acquisition of STADA’s U.S. operations represents a significant step forward for DAVA in the execution of its strategy of acquiring a strategic and diverse portfolio of specialty and generic pharmaceutical products,” said John H. Klein, Chairman and Chief Executive Officer of DAVA. Aram Moezinia, DAVA’s Executive Vice President of Global Business Development added, “not only does this acquisition add over fifteen generic products to DAVA’s current product offering, but also greatly enhances DAVA’s future growth with a development pipeline that is expected to consistently yield important additions to DAVA’s portfolio over the next five years.”

DAVA expects to complete the acquisition of STADA, Inc. during the third quarter of 2006.

About DAVA Pharmaceuticals, Inc.

DAVA Pharmaceuticals, Inc., a specialty pharmaceutical company, is focused on establishing and marketing a broad portfolio of pharmaceutical products. DAVA Pharmaceuticals is aggressively building its product portfolio through a combination of acquisitions, strategic alliances, in-licensing transactions, partnerships and development. For further information, please visit [www.davapharma.com](http://www.davapharma.com).